H. Liebman

发表

Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma.

B. Furie, R. A. Blanchard, B. Furie, 1984, The New England journal of medicine.

Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method

M. Broder, I. Yermilov, K. McCrae, 2020, Research and practice in thrombosis and haemostasis.

Des-γ-Carboxy (Abnormal) Prothrombin as a Serum Marker of Primary Hepatocellular Carcinoma

Shou-Dong Lee, B. Furie, R. A. Blanchard, 1984 .

Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin.

H. Liebman, 1989, Cancer research.

Des‐γ‐carboxy (abnormal) prothrombin and hepatocellular carcinoma: A critical review

H. Liebman, I. Weitz, 1993 .

Low-molecular-weight heparins in the prevention and management of malignancy-related venous thromboembolism

H. Liebman, C. O'Connell, I. Weitz, 2006 .

Prediction and Prevention of Cancer-Associated Thromboembolism.

A. Khorana, J. Zwicker, J. Connors, 2020, The oncologist.

Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.

D. Neuberg, M. Hidalgo, B. Furie, 2019, JCI insight.

Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).

E. Vicaut, A. Khorana, F. Shepherd, 2018, The oncologist.

Incidental venous thromboembolic events in cancer patients: what we know in 2016.

H. Liebman, C. O'Connell, 2016, Thrombosis research.

Approach to the management of incidental venous thromboembolic events in patients with cancer.

H. Liebman, C. O'Connell, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

The Oncologist ’ s Role in the Management of Venous Thromboembolism

A. Khorana, C. Kessler, H. Liebman, 2013 .

Treating venous thromboembolism in patients with cancer

H. Liebman, C. O'Connell, C. Piatek, 2012, Expert review of hematology.

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.

N. Mackman, N. Key, R. Kasthuri, 2010, Thrombosis research.

Acquired bleeding disorder in a patient with malignant lymphoma

H. Liebman, E. S. Lee, B. K. Hibsman, 2001, Cancer.

Tamoxifen‐associated venous thrombosis and activated protein C resistance due to factor V leiden

V. Israel, H. Liebman, I. Weitz, 1997, Cancer.

V. Lee, M. Rosen, H. Liebman, 1988, AJR. American journal of roentgenology.

Population Pharmacokinetic Analysis of Didanosine (2′,3′‐Dideoxyinosine) Plasma Concentrations Obtained in Phase I Clinical Trials in Patients with AIDS or AIDS‐Related Complex

F. Valentine, C. Mclaren, R. Dolin, 1992, Journal of clinical pharmacology.

Heparin-Induced Thrombocytopenia: Diagnosis and Management

H. Liebman, 2008, Vascular.

Management of cancer‐associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: reply

M. Di Nisio, A. Falanga, J. Thachil, 2015, Journal of thrombosis and haemostasis : JTH.

Management of cancer‐associated disseminated intravascular coagulation: guidance from the SSC of the ISTH

M. Di Nisio, A. Falanga, J. Thachil, 2015, Journal of thrombosis and haemostasis : JTH.

A systematic literature review on the use of platelet transfusions in patients with thrombocytopenia

A. Jakubowska, Z. Younossi, R. Tateishi, 2019, Hematology.

Progressive Prothrombotic State in Women With Advancing HIV Disease

C. Vigen, W. Mack, A. Levine, 2006, Journal of acquired immune deficiency syndromes.

Thrombocytopenia in Patients with Solid Tumors or Hematologic Malignancies

H. Liebman, C. Piatek, 2017 .

Thrombocytopenia in cancer patients.

H. Liebman, 2014, Thrombosis research.

Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient.

H. Liebman, 2005, Cancer control : journal of the Moffitt Cancer Center.

Cumulative probability of venous thromboembolism at 6 months using the expanded risk model before initiation of new therapy

H. Liebman, C. O'Connell, C. Piatek, 2012 .

Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH

A. Khorana, M. Di Nisio, Agnes Y. Y. Lee, 2015, Journal of thrombosis and haemostasis : JTH.

Thromboembolic complications of cancer: Epidemiology, pathogenesis, diagnosis, and treatment

H. Liebman, I. Weitz, D. Sutherland, 2003, American journal of hematology.

Risk of recurrent venous thromboembolism and major hemorrhage in cancer‐associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients

A. Shinagare, H. Hatabu, M. Tiseo, 2016, Journal of thrombosis and haemostasis : JTH.

Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review.

H. Liebman, I. Weitz, 1993, Hepatology.

Viral-associated immune thrombocytopenic purpura.

H. Liebman, 2008, Hematology. American Society of Hematology. Education Program.

Secondary immune thrombocytopenic purpura

R. Stasi, H. Liebman, 2007, Current opinion in hematology.

Severe depression of antithrombin III associated with disseminated intravascular coagulation in women with fatty liver of pregnancy.

H. Liebman, W. McGehee, D. Feinstein, 1983, Annals of internal medicine.

Clinical Predictors of Early Mortality in Colorectal Cancer Patients Undergoing Chemotherapy: Results From a Global Prospective Cohort Study

A. Khorana, F. Shepherd, G. Lyman, 2017, JNCI cancer spectrum.

Nattokinase atherothrombotic prevention study: A randomized controlled trial.

H. Meiselman, W. Mack, L. Dustin, 2021, Clinical hemorheology and microcirculation.

Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy

B. Furie, R. A. Blanchard, H. Liebman, 1984 .

Treatment of hepatitis C related thrombocytopenia with interferon alpha

H. Liebman, S. Rajan, 2001, American journal of hematology.

Antithrombin III and anti‐activated factor X activity in patients with acute promyelocytic leukemia and disseminated intravascular coagulation treated with heparin

A. Levine, H. Liebman, D. Feinstein, 1982, Cancer.

Hepatocellular carcinoma imaging

K. Weiss, V. Lee, H. Liebman, 1988, Journal of surgical oncology.

Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance.

C. Vigen, V. Duddalwar, W. Boswell, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond

H. Liebman, C. O'Connell, 2008, Expert review of hematology.

Pathobiology of Secondary Immune Thrombocytopenia

D. Cines, R. Stasi, H. Liebman, 2009, Seminars in Hematology.

A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

S. Solymoss, J. Julian, H. Liebman, 2012, Journal of thrombosis and haemostasis : JTH.

COAGULATION AND TRANSFUSION MEDICINE

R. Simms, H. Liebman, E. Vosburgh, 2015 .

The unique diagnostic and management challenge of a patient with concomitant anti-interferon-gamma autoantibody associated immunodeficiency syndrome, IgG4-related disease, and treatment refractory, disseminated mycobacterium avium complex infection

H. Liebman, M. Nguyen, Spencer Boyle, 2022, Allergy, Asthma & Clinical Immunology.

Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia.

V. Rowe, T. Alexy, H. Liebman, 2008, Journal of vascular surgery.

Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi‐row detector computed tomography scanning

P. Razavi, V. Duddalwar, W. Boswell, 2011, Journal of thrombosis and haemostasis : JTH.

Rivaroxaban for Thromboprophylaxis in High‐Risk Ambulatory Patients with Cancer

A. Khorana, G. Lyman, J. Eikelboom, 2019, The New England journal of medicine.

Rituximab treatment for resistant antiphospholipid syndrome.

D. Arkfeld, H. Liebman, S. Shinada, 2006, The Journal of rheumatology.

OC-03 Randomized phase II trial of an oral factor Xa inhibitor in patients with metastatic cancer on chemotherapy

M. Levine, J. Julian, H. Liebman, 2010 .

A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer.

S. Solymoss, M. Levine, J. Julian, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Deficiency of the specific granule proteins, R-binder/transcobalamin I and lactoferrin, in plasma and saliva: a new disorder.

R. Carmel, N. Borregaard, H. Liebman, 2001, American journal of medical genetics.

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti‐CD52 monoclonal antibody alemtuzumab (Campath‐1H)

H. Liebman, Xiuqing Ru, 2003, British journal of haematology.

Peri- and paracardial involvement in lymphoma: a radiographic study of 11 cases.

M. Jochelson, P. Mauch, H. Liebman, 1983, AJR. American journal of roentgenology.

Other immune thrombocytopenias.

H. Liebman, 2007, Seminars in hematology.

The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation.

D. Cines, H. Liebman, 2009, Hematology/oncology clinics of North America.

OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin.

S. Groshen, S. Tagawa, H. Liebman, 2016, Thrombosis research.

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)

A. Khorana, G. Lyman, J. Eikelboom, 2018, Blood.

Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials

D. Cines, J. Viallard, A. Giagounidis, 2013, European journal of haematology.

Incidental venous thromboembolism in oncology patients

A. Khorana, G. Agnelli, H. Liebman, 2012, Journal of thrombosis and haemostasis : JTH.

Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor.

H. Liebman, D. Feinstein, 2003, Thrombosis research.

The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease.

A. Kam, H. Liebman, L. Kam, 1998, Gastroenterology.

Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance

H. Liebman, W. McGehee, D. Sutherland, 1996, British journal of haematology.

Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.

B. Furie, H. Liebman, D. L. Diuguid, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.

B. Furie, B. Furie, H. Liebman, 1985, Proceedings of the National Academy of Sciences of the United States of America.

Alcoholic hepatitis: granulocyte chemotactic factor from Mallory body-stimulated human peripheral blood mononuclear cells.

M. Tong, H. Liebman, M. Peters, 1983, Clinical immunology and immunopathology.

Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.

H. Liebman, T. Cooley, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials

J. Lambert, G. Drusano, F. Valentine, 1992, Antimicrobial Agents and Chemotherapy.

Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.

S. Kelley, C. Mclaren, H. Liebman, 1990, Reviews of infectious diseases.

Management of immune-mediated cytopenias in pregnancy.

H. Liebman, M. Akhtari, C. Piatek, 2015, Autoimmunity reviews.

Response to treatment with the leukocyte-derived immunomodulator IMREG-1 in immunocompromised patients with AIDS-related complex. A multicenter, double-blind, placebo-controlled trial.

M. Gottlieb, L. Cone, D. Henry, 1991, Annals of internal medicine.

Chemotherapy-Induced Activation of Hemostasis: Effect of a Low Molecular Weight Heparin (Dalteparin Sodium) on Plasma Markers of Hemostatic Activation

C. Presant, V. Israel, J. Waisman, 2002, Thrombosis and Haemostasis.

American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer.

G. Raskob, C. Flowers, M. Somerfield, 2007, Journal of oncology practice.

Unsuspected Pulmonary Emboli Identified on Routine Cancer Staging MDCT Scans: Impact on Cancer Survival

P. Razavi, W. Boswell, H. Liebman, 2008 .

Anticoagulation is an effective treatment for aortic mural thrombi.

V. Rowe, H. Liebman, M. Bowdish, 2002, Journal of vascular surgery.

Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review

L. Grazette, David J. Hermel, J. Shinbane, 2020, EJHaem.

Isolation and Characterization of a Hepatoma-associated Abnormal (Des-7-carboxy)prothrombin1

H. Liebman, 2006 .

Ticlopidine‐induced aplastic anemia: Development of chromosomal abnormalities and response to immunosuppressive therapy

H. Liebman, V. Pullarkat, J. Murata-Collins, 2000, American journal of hematology.

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.

P. Razavi, N. Mackman, B. Furie, 2012, Thrombosis research.

Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism

H. Liebman, V. Pullarkat, S. Iqbal, 2002, British journal of haematology.

Cancer prognosis in patients with venous thromboembolism (VTE) and patients with clinical and laboratory biomarkers predictive of VTE risk.

H. Liebman, 2018, Thrombosis research.

Chapter 157 – Hematologic Manifestations of HIV/AIDS

A. Tulpule, H. Liebman, 2018 .

Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study

H. Al‐Samkari, H. Liebman, A. Cuker, 2022, British journal of haematology.

OC-06 Tissue factor-bearing microparticles are associated with an increased risk of venous thromboembolic events in cancer patients

B. Furie, J. Zwicker, B. Furie, 2007 .

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

C. Flowers, A. Khorana, C. Francis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII

H. Liebman, A. Galvez, J. Chediak, 2000, American journal of hematology.

Approach to the treatment, characterization and diagnosis of an acquired auto‐antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature

G. D. del Zoppo, H. Liebman, D. Feinstein, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX.

H. Liebman, 1993, European journal of biochemistry.

The ITP syndrome: pathogenic and clinical diversity.

E. L. Luning Prak, J. Bussel, D. Cines, 2009, Blood.

Seasonal variations in fatty acids of a migratory bird with and without a controlled diet

H. Liebman, M. L. Morton, 1974 .

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

A. Tulpule, F. Muggia, A. Levine, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.

J. Ritter, C. Mclaren, H. Liebman, 1990, The New England journal of medicine.

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)

H. Liebman, S. Sadeghi, S. Sadeghi, 2002, Annals of the rheumatic diseases.

Pulmonary Kaposi sarcoma in patients with AIDS: scintigraphic diagnosis with sequential thallium and gallium scanning.

D. R. Parker, M. O'brien, V. Lee, 1991, Radiology.

Hepatic Vitamin K‐Dependent Carboxylation of Blood‐Clotting Proteins

B. Furie, B. Furie, H. Liebman, 2007 .

Understanding Immune Thrombocytopenia: Looking Out of the Box

F. Cavalli, B. Godeau, T. Kühne, 2021, Frontiers in Medicine.

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

J. George, J. Bussel, C. Kessler, 2008, The Lancet.

Isolation and characterization of a hepatoma-associated abnormal (des-gamma-carboxy)prothrombin.

H. Liebman, 1989, Cancer research.

A glycosaminoglycan inhibitor of thrombin: A new mechanism for abnormal hemostatic assays in cancer

R. Comenzo, H. Liebman, S. T. Allen, 1991, American journal of hematology.

Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease.

M. Beltangady, S. Kelley, M. Rozencweig, 1992, Blood.

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia

H. Liebman, E. Cheung, 2009, Biologics : targets & therapy.

Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in Malignancy

D. Neuberg, B. Furie, J. Zwicker, 2009, Clinical Cancer Research.

Predictive model of venous thromboembolism in endometrial cancer.

K. Matsuo, L. Roman, L. Muderspach, 2013, Gynecologic oncology.

Risk of Recurrent Venous Thromboembolism and Major Bleeding in Cancer-Associated Incidental Pulmonary Embolism Amongst Treated and Untreated Patients: A Pooled Analysis of 926 Patients

A. Shinagare, H. Hatabu, M. Tiseo, 2014 .

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

C. Flowers, A. Khorana, C. Francis, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP).

J. Bussel, D. Cines, E. Grabowski, 2007, Blood.

Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.

M. Kaplan, J. Bennett, S. Kornblau, 1995, The New England journal of medicine.

Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics.

H. Liebman, V. Pullarkat, 2011, Hematology. American Society of Hematology. Education Program.

Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia

J. Bussel, P. Sandset, M. Thomassen, 2019, Platelets.

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

H. de Haard, A. Newland, M. Michel, 2019, American journal of hematology.

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group.

J. Bussel, V. Blanchette, D. Cines, 2013, Blood.

Effi cacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial

J. George, J. Bussel, C. Kessler, 2008 .

SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP

J. Bussel, C. Kessler, A. Leavitt, 2022, Blood.

SARS-CoV-2 Vaccination and Immune Thrombocytopenia in de novo and pre-existing ITP patients

Eun-Ju Lee, J. Bussel, C. Kessler, 2021, Blood.

Corticosteroid overuse in adults with immune thrombocytopenia: Cause for concern

H. Liebman, A. Cuker, 2021, Research and practice in thrombosis and haemostasis.

Low‐dose anti‐CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study

J. Bussel, D. Goldenberg, W. Wegener, 2013, British journal of haematology.

Depression of functional and antigenic plasma antithrombin III (AT‐III) due to therapy with L‐asparaginase

H. Liebman, M. Patch, W. McGehee, 1982, Cancer.

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Gary H Lyman, Christopher R Flowers, C. Flowers, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center

H. Liebman, C. O'Connell, I. Weitz, 2019, Platelets.

Successful therapy of convoluted T-lymphoblastic lymphoma in the adult.

A. Paganini-Hill, S. Forman, R. Lukes, 1983, Blood.

Immunomodulatory Drugs and Monoclonal Antibodies

H. Liebman, 2018 .

Are Tpo agonists an option for ITP in pregnancy?

H. Liebman, 2020, Blood.

Immune modulation for autoimmune disorders: evolution of therapeutics.

H. Liebman, 2016, Seminars in hematology.

Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders.

H. Liebman, 2009, Seminars in hematology.

Three Gaucher-Disease-Producing Mutations in a Patient with Gaucher Disease: Mechanism and Diagnostic Implications

E. Beutler, H. Liebman, T. Gelbart, 2001, Acta Haematologica.

Thyroid disease in patients with immune thrombocytopenia.

H. Liebman, E. Cheung, 2009, Hematology/oncology clinics of North America.

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer.

Gary H Lyman, Mohammad Jahanzeb, David Trent, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Subcutaneous Kaposi's Sarcoma Thallium Scan Demonstration

V. Lee, H. Liebman, J. O’keane, 1990, Clinical nuclear medicine.

Life‐threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab

H. Liebman, I. Shulman, I. Weitz, 2015, Transfusion.

Bone marrow response in treated patients with Gaucher disease: evaluation by T1-weighted magnetic resonance images and correlation with reduction in liver and spleen volume

M. Terk, H. Liebman, S. Dardashti, 2000, Skeletal Radiology.

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor‐bearing microparticles: a randomized‐controlled phase II trial (the Microtec study)

D. Neuberg, A. Bullock, H. Lenz, 2013, British journal of haematology.

Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy

T. Dorff, D. Skinner, D. Quinn, 2008, BJU international.

Hepatitis C virus‐related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura

H. Liebman, B. Espina, S. Rajan, 2005, British journal of haematology.

Metabolism of methotrexate in man after high and conventional doses.

R. Chlebowski, H. Liebman, K. Chan, 1980, Research communications in chemical pathology and pharmacology.

Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial

A. Khorana, G. Lyman, J. Eikelboom, 2017, Thrombosis and Haemostasis.

Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

J. Bussel, C. Kessler, D. Cines, 2021, Blood.

Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom.

H. Dombret, M. Tallman, A. Falanga, 2005, Leukemia research.

A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

H. Liebman, C. O'Connell, I. Weitz, 2019, Acta Haematologica.

Comparison of the native prothrombin antigen and the prothrombin time for monitoring oral anticoagulant therapy.

B. Furie, R. A. Blanchard, B. Furie, 1984, Blood.

Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism.

P. Razavi, H. Liebman, C. O'Connell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.

B. Furie, J. Ware, D. Stafford, 1989, The Journal of biological chemistry.

Chemotherapy-Induced Hemostatic Activation and Thrombosis in Cancer

H. Liebman, I. Weitz, 2007 .

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

M. Hirsch, A. Caliendo, R. D’Aquila, 1993, Antimicrobial Agents and Chemotherapy.

Clinical roundtable monograph. The oncologist's role in management of venous thromboembolism.

A. Khorana, C. Kessler, H. Liebman, 2011, Clinical advances in hematology & oncology : H&O.

The role of oral anticoagulants in tumor biology.

H. Liebman, I. Weitz, 2007, Seminars in Thrombosis and Hemostasis.

The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa.

B. Furie, B. Furie, H. Liebman, 1987, The Journal of biological chemistry.

Phase I/II Study of Subcutaneous Injections of Low-Dose Anti-CD20 Veltuzumab in Relapsed Immune Thrombocytopenia,

J. Bussel, D. Goldenberg, W. Wegener, 2011 .

AIDS in intravenous drug users: issues related to enrollment in clinical trials.

D. Craven, H. Liebman, K. Steger, 1990, Journal of acquired immune deficiency syndromes.

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia

J. Bussel, D. Goldenberg, W. Wegener, 2016, Haematologica.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

C. Flowers, A. Khorana, G. Lyman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

What do healthcare providers ask their patients with immune thrombocytopenia?

J. Bussel, H. Liebman, D. Kuter, 2010, American journal of hematology.

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

C. Flowers, A. Khorana, C. Francis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ITP syndrome: pathogenic and clinical diversity.

E. L. Luning Prak, J. Bussel, D. Cines, 2009, Blood.

What do healthcare providers ask their patients with immune thrombocytopenia?

J. Bussel, H. Liebman, D. Kuter, 2010, American journal of hematology.

Immune modulation for autoimmune disorders: evolution of therapeutics.

H. Liebman, 2016, Seminars in hematology.

Thrombocytopenia in cancer patients.

H. Liebman, 2014, Thrombosis research.

The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation.

D. Cines, H. Liebman, 2009, Hematology/oncology clinics of North America.

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.

N. Mackman, N. Key, R. Kasthuri, 2010, Thrombosis research.

Guideline : Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

G. Raskob, C. Flowers, M. Somerfield, 2007 .

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)

H. Liebman, S. Sadeghi, K. Arzoo, 2002, Annals of the rheumatic diseases.